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A B S T R A C T
Cardiac arrest effectiveness trials have traditionally reported outcomes that focus on survival. A lack of con-
sistency in outcome reporting between trials limits the opportunities to pool results for meta-analysis. The
COSCA initiative (Core Outcome Set for Cardiac Arrest), a partnership between patients, their partners, clin-
icians, research scientists, and the International Liaison Committee on Resuscitation, sought to develop a con-
sensus core outcome set for cardiac arrest for effectiveness trials. Core outcome sets are primarily intended for
large, randomised clinical effectiveness trials (sometimes referred to as pragmatic trials or phase III/IV trials)
rather than for pilot or efficacy studies. A systematic review of the literature combined with qualitative inter-
views among cardiac arrest survivors was used to generate a list of potential outcome domains. This list was
prioritised through a Delphi process, which involved clinicians, patients, and their relatives/partners. An in-
ternational advisory panel narrowed these down to 3 core domains by debate that led to consensus. The writing
group refined recommendations for when these outcomes should be measured and further characterised relevant
measurement tools. Consensus emerged that a core outcome set for reporting on effectiveness studies of cardiac
arrest (COSCA) in adults should include survival, neurological function, and health-related quality of life. This
should be reported as survival status and modified Rankin scale score at hospital discharge, at 30 days, or both.
Health-related quality of life should be measured with ≥1 tools from Health Utilities Index version 3, Short-
Form 36-Item Health Survey, and EuroQol 5D-5L at 90 days and at periodic intervals up to 1 year after cardiac
arrest, if resources allow. © 2018 European Resuscitation Council and American Heart Association, Inc.
Published by Elsevier B.V. All rights reserved.
Introduction
Sudden cardiac arrest is one of the leading causes of death in in-
dustrialised nations. In the United States,≈360 000 cardiac arrests are
attended by emergency services each year, with only 10.6% of patients
surviving to hospital discharge [1]. Similar statistics apply across
Europe and all other industrialised areas worldwide [2,3]. However,
survival rates vary widely both globally [4] and regionally [5,6], with
4-fold or more regional variations reported. These low and variable
survival rates highlight the importance of research that seeks to im-
prove patient outcomes.
Randomised trials are important tools for evaluating the clinical
efficacy and cost-effectiveness of interventions for in- and out-of-hos-
pital cardiac arrest. Two broad types of trials have been
described—efficacy and effectiveness. Efficacy (sometimes called ex-
planatory) trials aim to test whether an intervention works under op-
timal situations. Effectiveness (sometimes called pragmatic) trials are
designed to assess how well an intervention works in routine clinical
practice [7]. Ordinarily, efficacy trials focus on assessing the impact of
an intervention on a short-term outcome that is well correlated with
long-term prognosis. Effectiveness trials seek to provide evidence of the
longer-term health impact of an intervention [8,9]. Evaluated outcomes
can include clinical, clinician-reported, and patient-reported outcomes
and resource use or economic impact. Clinical trials provide essential
evidence of the relative benefit of an intervention for stakeholders as
diverse as clinicians, patients, and policy makers. Outcome selection is,
therefore, an important aspect of trial design [9,10].
Sometimes multiple trials might evaluate the same intervention in
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different settings. Reconciling disparate trial results can be challenging
if each trial evaluated different outcomes at different time points. A
systematic review of cardiac arrest trials published between 2000 and
2012 included 61 publications that identified> 160 different trial
outcomes [11]. No single outcome was reported across all trials. The
majority of outcomes reflected short-term clinical and clinician-re-
ported outcomes, focusing on pathophysiological manifestations and
process-based measures. Although survival was the most commonly
reported outcome, 39 different definitions of survival were used. Pa-
tient-reported outcomes [12] were rarely reported, although more re-
cent trials have included these outcomes [13,14]. This suggests that
essential evidence of the impact of care from the survivors’ perspective
is currently missing from clinical trials.
Adopting a consistent approach to outcome reporting for effective-
ness trials has the potential to reduce heterogeneity in reporting, im-
prove transparency in outcome selection, reduce reporting bias, and
increase information available to pool for meta-analysis. Standardised
reporting frameworks have been developed for reporting the findings of
observational studies drawn from resuscitation registries [15,16]. These
frameworks recommend 23 core data elements and 30 supplementary
elements across the 5 domains of system, dispatch, patient, process, and
outcome [17]. International guidelines exist for core outcomes to use in
effectiveness trials in patients with other conditions [18]. Becker et al.
[19] considered choices of primary outcomes across a range of re-
suscitation science studies but concluded that no single primary out-
come was appropriate for all studies of cardiac arrest; however, no
international guidelines exist to define a focused core outcome set
(COS) for use in effectiveness trials in patients with cardiac arrest.
The COMET initiative (Core Outcome Measures for Effectiveness
Trials) promotes the development and application of agreed standar-
dised sets of outcomes known as COS [20]. A COS is defined as a small,
standardised group of outcomes that should be measured and reported,
as a minimum, in all effectiveness trials for a specific health area
[20,21]. Effectiveness trials should aim to capture the COS as part of
their a priori-defined primary or secondary outcomes.
The COSCA initiative (Core Outcome Set for Cardiac Arrest), in
collaboration with the International Liaison Committee on
Resuscitation (ILCOR), sought to develop a COS for cardiac arrest ef-
fectiveness trials covering both in- and out-of-hospital cardiac arrest.
This consensus article draws on the views and experiences of patients,
the public, clinicians, policy makers, researchers, and the international
perspectives represented through the ILCOR collaborative network. The
process was informed by systematic reviews of the literature, as well as
qualitative research involving cardiac arrest survivors. A total of 168
participants used a Delphi process to draft a core cardiac arrest outcome
set, and a 2-day meeting was convened to develop consensus re-
commendations.
Methods
The available evidence associated with the development of COS
[18,20] and the websites of key COS development groups (COMET and
OMERACT [Outcome Measures in Rheumatoid Arthritis Clinical Trials],
later renamed Outcome Measures in Rheumatology) informed our ap-
proach. The project was registered with the COMET initiative [22].
Ethical approval was obtained from the National Health Service Black
Country Research Ethics Committee (13/WM/0464) to enable patients
and their partners to participate.
Development of a COS involved 2 key steps: development of a core
domain set (ie, what to measure) followed by identification of appro-
priate measurement tools (ie, how to measure) [18,20]. A core domain
set was defined as referring to the minimum number of health domains
(outcomes or aspects of health) that must be assessed. That is, it spe-
cifies what should be measured. Importantly, this stage was driven by
what is important and not how an outcome is assessed. The second
stage involved the establishment of a core outcome measurement set,
that is, the specific methods of assessment (ie, how to measure) for the
domains identified in step 1. The selection of measurement tools was
informed by an appraisal of measurement quality, relevance, and fea-
sibility.
The OMERACT initiative suggests that a COS should seek to include
at least 1 health domain across each of 4 core areas of health (Fig. 1): 3
core areas consider the impact of a health condition (ie, survival, life
impact, economic impact/resource use), and the fourth core area re-
flects any pathophysiological manifestations associated with the con-
dition [18]. Several reviews [11,23,24] suggest that these domains are
relevant and encompass the large number of outcomes assessed in
cardiac arrest trials.
To develop the consensus outcome criteria, a 4-stage approach was
used, which consisted of the following steps, each of which is explained
Fig. 1. OMERACT framework 2.0 modified for cardiac arrest. ICU indicates intensive care unit; OMERACT, Outcome Measures in Rheumatology; QOL, quality of life;
and ROSC, return of spontaneous circulation. Reprinted from Boers et al. [18] Copyright © 2014, The Authors. https://creativecommons.org/licenses/by-nc-nd/3.0/.
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in detail: (1) stage 1: generation of an extensive list of potential out-
comes across 4 core areas of health; (2) stage 2: an international Delphi
approach to refine and prioritise a list of potential outcomes; (3) stage
3: an international expert panel meeting; and (4) stage 4: synthesis of
findings and recommendations for measurement tools.
Stage 1: Generation of an Extensive List of Potential Outcomes Across 4 Core
Areas of Health
This stage was informed by a systematic review of the literature and
qualitative interviews with cardiac arrest survivors and their partners.
The systematic review focused on the identification of outcomes re-
ported from randomised controlled trials that enrolled adults who had
sustained a cardiac arrest [11]. The findings from the systematic review
were supplemented by conducting semistructured interviews with adult
cardiac arrest survivors (and, if available, their partners) between 3 and
12 months after discharge from the hospital after their cardiac arrest.
Interviews were conducted, recorded, and transcribed with NVivo (QSR
International, London, United Kingdom) by Dr Whitehead. Data were
analysed using interpretative phenomenological analysis, which seeks
to capture the individual’s experience of a phenomenon and how they
understand their experiences [25]. Findings from the systematic review
and qualitative research were synthesised to produce an extensive list of
potential outcomes. These were grouped under the OMERACT core area
headings of survival, life impact, resource use/economic, and patho-
physiological manifestations of cardiac arrest for consideration in stage
2.
Stage 2: International Delphi Approach to Refine and Prioritise List of
Potential Outcomes
The list of potential outcomes identified during stage 1 were placed
into an online survey tool (SurveyMonkey, Dublin, Ireland). Separate
surveys were developed for healthcare professionals and patients/pa-
tient advocates. The ILCOR network of 7 regional resuscitation councils
was used to solicit the views of healthcare professionals and patient and
public advocates. Each ILCOR member (n=27) was asked to invite 6
healthcare professionals and 3 patients to participate in the relevant
surveys by E-mail. The outcomes were prioritised in 2 rounds.
Questions were structured to allow participants to rate the importance
of each outcome at 5 different time points across the patient journey:
during cardiopulmonary resuscitation (CPR), immediately after CPR,
during hospitalisation, at hospital discharge, and within the first year
after the cardiac arrest. In the first round, survey participants were also
given the opportunity to suggest additional outcomes they considered
important if they were not currently included in the survey. At the end
of each round, outcomes rated as being of critical importance by> 70%
of respondents and rated as being of limited importance by< 15% of
respondents were advanced for additional consideration by the expert
panel in stage 3. Similarly, those outcomes rated of limited importance
by>70% of respondents and of critical importance by<15% of re-
spondents were discarded. The findings from the first round were
summarised and presented for a second round of prioritisation. Any
new suggestions were included in the second round. The second round
of prioritisation differed by asking participants to rank outcomes ac-
cording to importance. Outcomes that received strong support (> 70%
agreement) were also advanced for consideration by the expert panel in
stage 3. Outcomes that received moderate support (60%–69% agree-
ment) were also presented to the expert panel in stage 3.
Stage 3: International Expert Panel Meeting
The aim of the international expert panel was to consider the
shortlist of outcomes identified during stage 2 and select a COS com-
prising 4 to 8 outcomes and make recommendations of measurement
tools to capture those outcomes. A 2-day consensus meeting was con-
vened in Prague, Czech Republic, in October 2015. A group of experts
uninvolved in previous stages was purposefully selected to capture
those involved in clinical research (clinicians, clinical trialists, metho-
dologists), experts in the use of measurement tools for cardiac arrest,
healthcare providers involved in treating patients with cardiac arrest
(physicians, nurses, paramedics, allied health professionals), and sur-
vivors of cardiac arrests and patient advocates.
Before the meeting, the participants were sent a written summary of
the outcome selection process described above. At the start of the
meeting, an overview of steps undertaken and findings from stages 1
and 2 were presented. The shortlisted outcomes were presented in a
matrix that covered the OMERACT core area headings of survival, life
impact, resource use/economic, and pathophysiological manifestations
of cardiac arrest during CPR, immediately after CPR, during hospitali-
sation, at hospital discharge, and within the first year after the cardiac
arrest. Initial presentations were followed by semistructured, small-
group discussions that covered the 4 core areas. Each core area was
assigned a facilitator who supported 4 rounds of discussions on that
topic. Each discussion group included a survivor of cardiac arrest or a
patient advocate, as well as several researchers and clinicians who
participated in small-group discussion across each core area. Each
group nominated a recorder. The groups were tasked to consider the
importance, relevance, acceptability, and feasibility of the short-listed
outcomes as potential core outcomes for cardiac arrest effectiveness
trials. The facilitator encouraged all group members to participate in
discussions and shared key findings from each group with the next. This
enabled consideration of and building upon what other participants had
discussed, facilitated the identification of issues of agreement and dis-
agreement, and supported a flow of new ideas or key issues between
groups. Thereafter, participants reconvened in a whole-group discus-
sion session, in which facilitators and group recorders summarised
feedback from the small-group discussions, including areas of agree-
ment and disagreement. The large-group discussion sought to collec-
tively explore agreement and refine issues or concerns raised within
each core area. At the end of the first day, expert panel members were
invited to reflect on the day’s discussions and then vote for up to 7
outcomes they believed should be included as core outcomes. Secure
electronic votes were submitted by use of TurningPoint software and
ResponseWare keypads (Turning Technologies, Youngstown, Ohio).
The second day followed a similar model of large- and small-group
discussions designed to allow further discussion and reflection on the
optimal outcomes. A second round of voting was used to identify the
final list of core outcomes. Proceedings were captured in the form of
detailed written records from discussion groups, plenary sessions, and
the outcome of voting.
Stage 4: Synthesis of Findings and Recommendations for Measurement Tools
A writing group was appointed by ILCOR and endorsed by the
American Heart Association Manuscript Oversight Committee after re-
view for conflicts of interest. The charge to the group was to draw to-
gether and summarise the findings from stages 1 through 3.
The group met by teleconference on 8 occasions and face-to-face on 1
occasion.
The writing group reviewed and summarised the findings from
stages 1 through 3 presented in this scientific statement. The group
undertook further work with the intention of making recommendations
on relevant measurement tools for the outcome domains selected in
stage 3. This was informed by considering existing measurement tools
in cardiac arrest and other relevant diseases or injuries and discussing
their quality, acceptability, and feasibility for application in clinical
trials. Final recommendations were reached through discussion and
consensus among the writing group members.
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Results
Stage 1: Generation of an Extensive List of Potential Outcomes Across 4 Core
Areas (OMERACT Framework)
The systematic review identified 61 randomised trials that re-
ported 164 unique outcomes on 278 occasions [11]. The most fre-
quently reported outcome was survival (85% of trials). This included
return of spontaneous circulation (ROSC) before hospital admission,
in the emergency department, or at any point during the resuscita-
tion attempt. Survival was reported at various time points from
emergency department admission, hospital discharge, and through
to 3 years. There was a lack of consistency in definition and the time
points at which survival was assessed, although most studies (90%)
reported survival up to and including hospital discharge. Patho-
physiological outcomes (e.g., coronary perfusion pressure, arterial
blood gas results) and life impact were frequently reported, al-
though there was a lack of consistency in outcomes, measurement
tools, and the timings of assessments. Process of care (e.g., event
timings), response to treatment (e.g., temperature achieved in tar-
geted temperature management trials), quality of CPR, intervention
success rates (e.g., vascular access), and adverse outcomes were
reported in a quarter of studies. Writing group members identified
trials published more recently that reported outcomes in the domain
of life impact [13,14,26,27].
Eleven interviews (8 patients, 3 partners) were conducted to pro-
vide a detailed understanding of the lived experience of those surviving
cardiac arrest. Five key themes were identified by patients that re-
flected the disruption to normality caused by cardiac arrest (survival,
physical activities, emotional well-being, social well-being, and the
impact on others; Table 1).
The findings from the systematic review and patient/partner inter-
views were used to produce an extensive list of 53 potential outcomes,
encompassing survival (5), life impact (24), economic impact and re-
source use (10), and pathophysiological manifestations (14), which
were used in the stage 2 Delphi process.
Stage 2: International Delphi Approach to Refine and Prioritise Long List of
Potential Outcomes
Ninety-nine healthcare professionals, 62 cardiac arrest survivors,
and 7 relatives of cardiac arrest victims from 15 countries participated
in the Delphi survey. The clinician group included 48 physicians, 12
nurses, 21 allied health professionals, 6 academics and 12 others. By the
end of the 2 Delphi rounds, 25 outcome domains were prioritised
(Fig. 2).
Stage 3: International Expert Panel Meeting
A total of 23 expert panel members (including 2 survivors, 1
partner, and 1 patient advocate) participated from 11 countries (United
Kingdom, the Netherlands, Finland, Germany, Belgium, Sweden, United
States, Canada, Singapore, Australia, and New Zealand). The core
outcome discussions and recommendations are summarised below.
Pathophysiological Manifestations
The expert panel considered circulatory function, respiratory
Table 1
Themes From Patient and Partner Interviews Relating to Disruption to
Normality
Theme Examples
Survival Closeness to death
Gratitude to be alive
Impairment and impact on
activities
Fatigue
Breathlessness
Vision
Muscle weakness
Pain (e.g., fractured ribs)
Activities of daily living/increased
dependence
Cognitive function
Emotional well-being Anxiety
Confidence
Depression
Self-esteem
Personality changes
Frustration
Social well-being and
participation
Participation (role: job, voluntary, career)
Participation (leisure: hobbies, sports)
Participation (social activities)
Participation (family: relationships, intimacy)
Impact on others Increased work/care
Impact to participation—hobbies, work
Strain on relationships
Worry
Fig. 2. Outcome domains presented for discussion at COSCA meeting. Circles
indicate healthcare professionals and researchers; triangles indicate patients
and partners. Grey fill indicates strong consensus (< 70%); white fill indicates
moderate support. Grey boxes were not rated or ranked on their importance.
COSCA indicates Core Outcome Set for Cardiac Arrest; and CPR, cardio-
pulmonary resuscitation. *Hospital-free survival and CPR process measures
were introduced during expert panel meeting.
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function, and brain function as potential core outcomes. There was
general agreement that the assessment of these outcomes is of high
importance during and immediately after cardiac arrest. They become
less important once ROSC has been achieved. Consideration was given
to the potential for pathophysiological measures to act as surrogate
assessments for longer-term functional outcomes. For example, specific
neuroimaging/electrophysiological tests might be a useful surrogate to
reflect the impact of a cardiac arrest on brain function [28]. The panel
considered these outcomes might be valuable during the validation of
new interventions and advancing discovery, for example, in efficacy
trials; however, there was general agreement that the assessment of
specific pathophysiological manifestations as core outcomes across the
wide range of effectiveness trials in this field is of limited value.
The importance of reporting adverse events was discussed at length.
There was general agreement that the reporting of adverse events
should occur in accordance with Good Clinical Practice guidelines,
which are relevant to all clinical trials, rather than as a core outcome
specific for cardiac arrest.
Although not introduced during the Delphi survey, participants
discussed the importance of the quality of CPR (ie, CPR process) and its
potential use as a core outcome. Such measures could include com-
pression rate, preshock pause duration, compression depth, or time to
intervention. There was unanimous consensus that the processes of CPR
are important contributors to outcome after cardiac arrest. Participants
recognised that CPR can be initiated or completed before a study in-
tervention is applied. Although CPR process could be an indicator of the
quality of a resuscitation system of care or a potential modifier of the
effect of a study intervention, it was concluded that CPR process should
not be a core outcome for effectiveness trials. This should not limit
researchers from reporting CPR quality matrices to enable the assess-
ment of associations between CPR performance and COS categories.
Where such data are reported, use of standardised definitions [29] and
time intervals could reduce variation in reporting [30].
Survival
The expert panel discussed the relative importance of short-term
survival, such as ROSC. The outcome was thought to be important in
efficacy studies, which seek to advance discovery in this field, but
contributed less toward understanding the longer-term aspects of sur-
vival.
Hospital-free survival (number of days alive and permanently out-
side a hospital in the first 30 days after cardiac arrest) was introduced
during discussions. It was recently used in a large, pragmatic cardiac
arrest trial [31] and offers potential statistical efficiencies over di-
chotomous outcomes [32,33]. Challenges can exist around the inter-
pretation of a composite outcome, which combines survival with length
of hospital stay.
The panel concluded that longer-term survival (alive/dead) should
be the core survival outcome.
Life Impact
Patient/partner participants voiced a number of potentially over-
lapping domains that can be affected after a cardiac arrest, which in-
cluded cognition and consciousness, physical symptoms, activities of
daily living, health-related quality of life (HRQoL), emotional well-
being, family impact, participation, and fatigue. It was agreed that
among the most common and significant impacts of cardiac arrest are
potential changes to cognition and neurological functioning. Other
contributors to daily life, such as physical, social, and emotional
changes after returning home, were discussed and considered im-
portant. To capture these important domains of health, a multidomain
approach, including assessing an individual’s HRQoL after arrest, was
favoured.
The panel reached consensus that neurological function and HRQoL
should be included as core outcomes.
Economic Evaluation
Although domains reflective of this core area were not prioritiszed
by participants in the Delphi survey, the importance attributed to this
core area in the OMERACT initiative suggested that further discussion
of the relative importance of this core area and possible domains was
required. Group discussion highlighted the complexities of capturing
sufficient information to allow for a full economic analysis of costs
related to cardiac arrest. Although economic evaluation was judged to
be important, it was agreed that there was insufficient evidence to in-
form categorisation currently. As a result, economic measures were not
suggested as a core outcome.
Stage 4: Recommendations for Measurement Tools and Timing of
Measurement
Survival
Survival to discharge and survival to 30 days were considered to be
better indicators of patient recovery than shorter-term survival, such as
survival to admission or 4 to 6 hours after emergency department ar-
rival. Discussion highlighted international variation in the feasibility of
collecting information on survival at discharge and survival at 30 days.
Both time points have limitations: survival to discharge is limited by
cultural differences (whether patients are discharged home to die or die
predominantly in the hospital) and health system differences (efficiency
of discharge processes; whether long-term care is provided in the hos-
pital or in home care settings). This can limit comparisons across dif-
ferent health systems. Survival to specific intervals (e.g., 30 days) after
arrest can avoid some of these limitations but in some settings requires
consent, which, as noted elsewhere, can introduce bias through higher
rates of loss to follow-up.
The writing group concluded that neither time point is perfect, and
for consistency with the Utstein recommendations [17], it was agreed
either survival to hospital discharge or survival to 30 days would be
acceptable to report as core outcomes. Researchers are encouraged to
report both measures if feasible but should avoid reporting these as a
composite outcome (survival to discharge or survival to 30 days) be-
cause this impairs pooling results in a meta-analysis.
Neurological Function
Five clinician-completed measures—the Cerebral Performance
Category (CPC) [34], Structured CPC (assessment by semistructured
interview) [35], CPC-Extended [36], Glasgow Outcome Scale–Extended
[37], and modified Rankin Scale (mRS) [38]—were considered. Mod-
erate associations between the tools suggest that they measure related
but not identical constructs [13,35,39–42]. The CPC was not highly
endorsed because of the lack of discrimination between scores and the
potential for ceiling effects and overestimation of function [14,43–46].
The CPC-Extended was considered to show good evidence of content
validity, reliability, acceptability, and feasibility, although its use in
cardiac arrest survivors was limited at this time [36]. The mRS and
Glasgow Outcome Scale–Extended appear to provide improved granu-
larity [41,43]. The mRS has been used more extensively in cardiac ar-
rest survivors [13,41,47–55] than the Glasgow Outcome Sca-
le–Extended [44,56] or CPC-Extended [37].
The writing group reached unanimous agreement that the mRS
should be the outcome measurement tool of choice for neurological
function. The mRS is a brief, clinician-completed, ordinal hierarchical
rating scale used to determine a summary score of global disability
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[57,58] after a neurological event or condition. The mRS captures im-
pairment of physical and cognitive abilities. Questions primarily focus
on limitations in basic, instrumental, and more advanced daily activ-
ities and restrictions in ability to participate in normal social roles
[58,59]. There is evidence that it can discriminate between levels of
mild and moderate disability [58]. It does not, however, provide de-
tailed information of residual impairments and is unable to differentiate
between whether effects are attributable to neurological or other
sources of disability [58,60].
How to Complete
mRS completion is preferably measured by direct interview with the
patient and any relevant caregiver, either face-to-face or by telephone
(Table 2) [57]. Nonstandardised interview administration requires ≈5
minutes [57]. When patients are unable to participate in interviews
because of physical, language, or cognitive impairment, proxy com-
pletion—that is, completion by informants, such as family members,
caregivers, or health professionals who know the patient well—can be
considered. However, proxy completion without the involvement of the
patient is associated with suboptimal levels of reliability and validity
[57,61]. Although some studies suggest that indirect mRS completion
from hospital records is less accurate [62], others suggest acceptable
reliability after chart review by trained health professionals [36,39].
Substantial inter-rater reliability of the mRS has been described [63]
although this can be improved through digital training [63], use of a
structured interview [59,64], or use of a web-based tool with 9 ques-
tions (mRS-9Q) and an mRS calculator [65]. Use of trained raters and a
structured approach to calculating the mRS score is recommended.
Raters should also be familiar with problems common after cardiac
arrest.
Timing
The advantages and disadvantages outlined above for reporting
survival status at discharge or at 30 days apply similarly to the re-
porting of favourable neurological function. Additional limitations of
measuring neurological function at discharge are that the patient will
not have been exposed to normal/their previous activities to allow
accurate determination of the relevant mRS category. The time of dis-
charge is also likely to be influenced by the degree and speed of re-
covery, with those having the greatest disabilities remaining in the
hospital longer. Additional challenges imposed by assessing neurolo-
gical function at 30 days include the requirement for the research team
to specifically follow up with the patient, because unlike mortality,
these data often are not tracked routinely. Incomplete follow-up confers
a risk of introducing attrition bias. Whichever time point is selected, the
outcome should be reported as measured on the day of the assessment
and not the best ever achieved.
The writing group accepted that there were advantages and dis-
advantages to both time points, and similar to our suggestion for as-
sessing survival status, mRS score at discharge or 30 days was
considered acceptable for reporting as a core outcome. Researchers can
report both time points if feasible but should avoid reporting as a
composite outcome (mRS score at discharge or 30 days) because this
impairs pooling results in a meta-analysis.
What to Report
Historically, cardiac arrest trials have dichotomised neurological
outcomes into favourable or unfavourable categories based on an mRS
cutoff of≤3 [17,66,67]. However, in stroke trials, an mRS score of≤1
[68] or≤ 2 [69] has been used to represent the cut off between fa-
vourable and unfavourable outcomes.
To enable consistent reporting and comparisons between articles,
the writing group advised that the core outcome be presented as the
number and percentage of patients in each of the 6 categories rather
than solely being categorised into favourable and unfavourable neu-
rological outcome groups. This approach also provides greater granu-
larity on clinically-relevant outcomes [70].
To facilitate the transition to mRS as the core outcome measurement
tool and to support backward comparability, the writing group was also
supportive of continued reporting of the CPC score over the next 5
years, in addition to the mRS score. Useful information for calculating
the mRS score can be found on the Internet [71].
The COSCA writing group suggested the use of the mRS version,
where category 4 (moderate severe disability) includes dependency to
attend to own bodily needs as separate from ability to walk unassisted
(or instead of and). Outcome after cardiac arrest is less influenced by
locomotor problems than after stroke, and this version will be more
sensitive in identifying extensive dependency related to severe cogni-
tive impairment in a patient still able to walk. This version is available
online [71]. The scoring is as follows: 0=no symptoms; 1=no sig-
nificant disability—able to carry out all usual activities, despite some
symptoms; 2=slight disability—able to look after own affairs without
assistance but unable to carry out all previous activities; 3=moderate
disability—requires some help but able to walk unassisted; 4=moder-
ately severe disability—unable to attend to own bodily needs without
assistance and/or unable to walk unassisted; 5=severe dis-
ability—requires constant nursing care and attention, bedridden, in-
continent; and 6=dead.
Health-Related Quality of Life
The writing group spent considerable time deliberating which tools
should be used to capture HRQoL after cardiac arrest. Key considera-
tions were the relevance or acceptability to cardiac arrest survivors,
feasibility (e.g., ease of use, information collection methods), the
measurement properties and their previous use in the cardiac arrest
patient population, and cost. The writing group prioritised 6 generic
measures of HRQoL for detailed consideration: 2 multi-item profile
measures (the Short-Form 36-Item Health Survey [SF-36] [72] and
Short-Form 12-Item Health Survey [SF-12] [73,74]) and 4 preference-
based, multiattribute utility measures (the 15-dimension Quality of Life
Table 2
Core Outcomes, Time Point, and Preferred Methods for Collection
Outcome Time Point Preferred Method Alternative Method
Survival 30 d or discharge Ambulance/hospital records
Death registry
Neurological function (mRS) 30 d or discharge Face-to-face interview by trained raters using mRS-9Q Informant interview
Telephone assessment
Review of hospital records
Quality of life 90 d Face-to-face
(proxy completion where respondents are unable to participate)
Telephone interviews
Postal questionnaire
mRS indicates modified Rankin Scale; and mRS-9Q, 9-question mRS.
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questionnaire [15-D] [75], the Health Utilities Index version 3 [HUI3]
[76], and both the original and revised versions of the EuroQol [EQ-5D-
3L [77] and EQ-5D-5L [78], respectively]). All preference-based mea-
sures include both descriptive systems and a utility index and hence
could be used in cost-utility evaluations [79].
The group was unable to reach consensus and recommend a single
tool among these measures. Patient and public partners highlighted that
none of the tools comprehensively captured their experiences of the
aftermath of a cardiac arrest. In online voting, the HUI3, followed by
the SF-36 and EQ-5D-5L, received the most support (Table 3). The
briefest measures are the EQ-5D-5L (5 items) and HUI3 (8 items); the
longest is the SF-36v2 (36 items). Although all measures are intended to
be measures of health status or HRQoL, the number of items and HRQoL
coverage vary (Table 3). The HUI3 and EQ-5D-5L have a preponderance
of items that relate to physical health, whereas items within the SF-
36v2 are equally distributed between physical and mental health [79].
Only the HUI3 includes items that measure cognition, speech, and
dexterity, which are concerns relevant to cardiac arrest survivors. Only
the SF-36v2 includes an assessment of fatigue.
Preference-based utility scores can be calculated for HUI3, EQ-5D-
5L, and SF-36v2 (in the form of the SF-6D [86]), which supports their
use in cost-utility evaluation. The SF-36v2 provides the most detailed
profile score; that is, separate scores are calculated across the 8 health
domains, providing a more detailed assessment of health status than is
otherwise afforded by the 2 summary scores. More limited descriptive
profile scores can also be reported for both the HUI3 and EQ-5D across
their 8 and 5 attributes, respectively. Normative population data are
available for all measures, which supports data interpretation and be-
tween-group comparisons. Estimates of meaningful change have been
calculated for all measures after completion by the general population
and specific patient groups, which further supports data interpretation.
License requests are required for all measures, but only the EQ-5D-5L is
free to use.
A review of published evidence on the reliability and validity of
these measures after completion by survivors of cardiac arrest demon-
strated that the strongest evidence was available for the HUI3, followed
by the SF-36v2 [87]. The EQ-5D-5L has not been evaluated in this
population; however, evaluations in comparable populations suggest
improved data quality and psychometric performance compared with
the original EQ-5D-3L [78].
In summary, multiple measures of HRQoL, including the SF-36v2,
EQ-5D-5L, and HUI3, are acceptable for measurement of outcomes in
trials enrolling patients with cardiac arrest. Each of these has strengths
and weaknesses compared with other measures available. HUI3 has
been applied frequently to patients with cardiac arrest and directly
measures cognition. The other measures are also acceptable.
How to Complete
Although all of the HRQoL measures discussed here were developed
to be self-completed, all have been successfully administered by inter-
view in person [40,42], via the telephone [13,56,88,89], or both [14]
in the cardiac arrest population. Postal self-completion, although pos-
sible, has been used infrequently. However, the ability to self-complete
a questionnaire after a cardiac arrest can be severely impaired by
cognitive impairment (which can result in an overestimation of ability)
[90], fatigue, or general poor health. Although proxy ratings of non-
observable constructs such as emotional well-being and cognition can
underestimate limitations [91,92], agreement is generally greater for
more physical attributes [91,93,94]. Cronberg et al. [14] described
interview-based proxy completion of the SF-36v2 with 8% of survivors
at 6-month follow-up. Where possible, proxy completion by
appropriate, well-informed assessors is suggested to ensure that the
views of survivors who are unable to self-report are included in trials
and the results do not underestimate the impact of cardiac arrest on
HRQoL [94].
Timing
There was consensus that HRQoL should be measured after the
patient’s discharge from the hospital. Patient recovery often continues
to 6 months and beyond. Three-quarters of patients of a working age
return to work after cardiac arrest at a median interval of 4 months
[95]. The optimal time points and frequency of follow-up need to be
considered in the context of study resources and overall study design. If
sufficient resources are available to measure postdischarge outcomes,
the group recommends, as a minimum, assessment at 90 days. The
group considered that this best balanced the trade-off between costs
and other implications associated with longer-term follow-up with the
positive effect of the value and stability of the data and is consistent
with the review of primary outcomes by Becker et al. [19]. However, it
is recognised that health status can continue to change in the sub-
sequent months and that capturing this change is important [41,95,96].
Therefore, the group agreed that HRQoL could also be assessed at 180
days or 1 year, or both. However, the longer duration of follow-up
would be associated with increased logistic challenges and could be
influenced by factors external to surviving a cardiac arrest.
Discussion
The COSCA writing group identified that survival, neurological
function, and HRQoL should be reported as core outcomes in cardiac
arrest effectiveness trials. Survival status should be reported at hospital
discharge, at 30 days, or both. Neurological function (measured with
the mRS) should be reported at hospital discharge, 30 days, or both.
HRQoL should be measured with ≥1 tools from the HUI3, SF-36v2, or
EQ-5D-5L at 90 days and at periodic intervals up to 1 year after cardiac
arrest, if resources allow.
COS are intended to enhance standardisation of outcomes that are
reported for effectiveness trials. As such, future cardiac arrest effec-
tiveness trials should include the core outcomes identified by COSCA as
part of the a priori-designated primary or secondary trial outcomes. The
COS are intended to be complementary to other outcome measures
relevant to the particular intervention under evaluation. The COS re-
commendations sit alongside, rather than replace, tools designed to
enhance the quality and transparency of health research, such as SPIRIT
(Standard Protocol Items: Recommendations for Interventional Trials)
[97] and CONSORT (Consolidated Standards of Reporting Trials) [98]
(Fig. 3). Earlier phase trials will typically focus primarily on measures
of efficacy, such as biomarkers, ROSC, or immediate survival, although
selected core outcomes could also be considered.
Traditionally, outcome assessment of patients experiencing cardiac
arrest has focused on survival rates and clinician-based assessments of
outcome [11]. However, the growth in patient-centred care and re-
cognition of the importance of seeking to understand the impact of
cardiac arrest from the perspective of the survivor demand a shift in the
way that outcomes (in particular, over the longer term) are assessed in
clinical trials. The use of well-developed questionnaires, which provide
an assessment of how patients feel, function, and live their lives because
of their health and health care, can provide essential patient-derived
information to enhance outcome reporting in clinical trials [99]. Such
questionnaires or patient-reported outcome measures can be simply
categorised as generic or specific (to a condition [e.g., diabetes mel-
litus], a problem [e.g., cognition], a function [e.g., activities of daily
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life], or a population [e.g., children]).
Generic measure of HRQoL, such as those short-listed in the COSCA
recommendations (HUI3, SF-36v2, EQ-5D-5L), includes multi-
dimensional concepts (physical, social, emotional, and mental func-
tioning) that provide a general assessment of HRQoL of relevance to
patients and the general population, facilitating between-group com-
parisons and ensuring that the patient perspective is captured in clinical
trials. Although the generic measures supported by COSCA start to
move the focus toward patient-centred outcomes, the current tools still
fail to comprehensively capture the breadth of outcomes and experi-
ences that matter most to cardiac arrest survivors [100–102]. As a
consequence, the impact of cardiac arrest and associated health care
might be incompletely assessed. Although a condition-specific measure
for survivors of cardiac arrest does not currently exist, measures specific
to problems of relevance to cardiac arrest survivors (e.g., cognition,
fatigue, anxiety, social participation) are available and have been used
increasingly in this population [13,14,26,27,103–105]. Although the
COSCA recommendations do not currently include guidance for ≥1
problems or function-specific measures, per good practice guidance for
outcome assessment [91,92], where possible, we encourage their in-
clusion. Although not yet evaluated in the cardiac arrest population, the
PROMIS initiative (Patient Reported Outcome Measures Information
System [106]) describes a range of fixed or dynamic (computer adap-
tive tests) self-report measures of physical, mental, and social health
appropriate for use with the general population and those with chronic
conditions and hence suitable for comparing the burden of illness and
treatment impact. The paucity of evidence to suggest which tools are
best suited highlights the need for further research in this area.
Collecting HRQoL measures as an outcome of a clinical trial can be
challenging and expensive. Sometimes, such data are missing from
patients with the poorest outcomes, which can result in systematic bias,
which cannot be ignored [107,108]. To maximise the quality and
timeliness of quality-of-life measures and reduce the risk of systematic
bias caused by missing data, standardised administration and routine
screening for avoidable missing data are advised [108–110]. The ap-
proaches used and handling of missing data should be detailed in the
study protocol and standard operating procedures [107,109].
The writing group was cognisant of the balance that needs to be struck
between the requirements of collecting the core outcomes identified by the
COSCA initiative at a time of constrained research resources and the need
to accelerate the pace of evidence-based change in resuscitation practices.
The overall efficiency of the research pathway can be improved through a
better understanding of the pathophysiology and effects of therapeutic
interventions from animal and laboratory studies. By establishing proof of
concept with evidence from early efficacy trials, internal pilot studies
could reduce redundancy in effectiveness trials [111–113]. Improving the
efficiency of the conduction of trials [114] and making use of registry data,
where possible [115], could reduce costs and shorten the time to complete
trials. The use of fixed dichotomous analysis of ordered categorical out-
comes is rarely the most statistically efficient approach and usually re-
quires a larger sample size to demonstrate efficacy than other approaches
[68]. Alternative analytical approaches such as shift analysis and ordinal
logistic regression, used widely in stroke research [68,70], require further
evaluation in the cardiac arrest population. A better understanding of
measurement properties of continuous outcomes, such as hospital-free
survival [32], might also aid reductions in sample size and trial costs.
Conclusions
Through a partnership between patients, partners, clinicians, and
researchers and endorsed by ILCOR, consensus emerged that a COS for
reporting on effectiveness studies of cardiac arrest (COSCA) should
include survival, neurological function, and HRQoL. To facilitate
meaningful comparisons across studies over time, survival status and
mRS at hospital discharge, 30 days, or both should be reported. HRQoL
should be measured with ≥1 tools from the HUI3, SF-36v2, or EQ-5D-
5L at 90 days and at periodic intervals up to 1 year after cardiac arrest,
if resources allow.
Fig. 3. Core outcome sets as part of Good Clinical
Practice. Clinical trials are conducted within the
overall framework of Good Clinical Practice, which
supports clear and transparent reporting. Core out-
come sets are suggested for inclusion as part of the a
priori-designated primary or secondary end points of
effectiveness trials. They enhance the quality and
transparency of health research promoted by SPIRIT
and CONSORT. CONSORT indicates Consolidated
Standards of Reporting Trials; EQ-5D-5L, 5-level EQ-
5D; HUI3, Health Utilities Index version 3; mRS,
modified Rankin scale; QoL, quality of life; SF-36, 36-
item Short Form Survey; and SPIRIT, Standard
Protocol Items: Recommendations for Interventional
Trials.
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